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Abstract
Background: Partial pancreatoduodenectomy is performed for malignant and benign diseases of the pancreatic
head region. The procedure is considered highly difficult and highly invasive. Postoperative pancreatic fistula (POPF)
is an important complication because of several consequent complications, including intraabdominal haemorrhage,
often increasing hospital stays and surgical mortality. Although many kinds of pancreaticojejunostomy aimed at
reducing POPF have been examined to date, the technique has not yet been standardized. We devised a new
method using double-coated polyglycolic acid felt after pancreaticojejunostomy. The aim of the PLANET-PJ trial is
to evaluate the superiority of polyglycolic acid felt reinforcement in preventing POPF after pancreaticojejunostomy
in patients undergoing partial pancreatoduodenectomy to previous anastomosis methods.
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Methods: Patients diagnosed with pancreatic or periampullary lesions in whom it is judged that the main
pancreatic duct diameter was 3 mm or less on the left side of the portal vein without pancreatic parenchymal
atrophy due to obstructive pancreatitis are considered eligible for inclusion. This study is designed as a multicentre
randomized phase III trial in Japan and the Republic of Korea. Eligible patients will be centrally randomized to either
group A (polyglycolic acid felt reinforcement) or group B (control). In total, 514 patients will be randomized in 31
high-volume centres in Japan and Republic of Korea. The primary endpoint is the incidence of POPF (International
Study Group of Pancreatic Surgery grade B/C).
Discussion: The PLANET-PJ trial evaluates the efficacy of a new method using double-coated polyglycolic acid felt
reinforcement for preventing POPF after pancreaticojejunostomy. This new method may reduce POPF.
Trial registration: ClinicalTrials.gov, NCT03331718. University Hospital Medical Information Network Clinical Trials
Registry, UMIN000029647. Registered on 30 November 2017. https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.
cgi?recptno=R000033874
Keywords: Pancreatoduodenectomy, Pancreaticojejunostomy, Postoperative pancreatic fistula, Polyglycolic acid felt,
International multicentre study
Background
Partial pancreatoduodenectomy is performed on malig-
nant and benign diseases of the pancreatic head region.
The procedure is considered highly difficult and highly in-
vasive. Pancreaticojejunostomy requires a high level of
surgical technique for anastomosing the residual pancreas
and jejunum. When implementing partial pancreatoduo-
denectomy, a high-volume centre with highly skilled sur-
geons is recommended. The incidence of complications
after partial pancreatoduodenectomy is reported to be
30–65%, higher than those of other digestive tract surger-
ies [1–10]. Among these complications, postoperative
pancreatic fistula (POPF) is generally recognized as an im-
portant complication, because intraabdominal haemor-
rhage can be fatal. Increases in postoperative hospital stay
and surgical mortality rates are also problems.
POPF was first standardized and reported in 2005
[11]. According to the latest International Study Group
of Pancreatic Surgery (ISGPS) criteria reported in 2016
[12], the former “grade A POPF” is now redefined and
called a “biochemical leak” because it has no clinical im-
portance and is no longer referred to a true pancreatic
fistula. Therefore, POPF has only grade B and grade C.
Grade B requires a change in the postoperative manage-
ment; drains are either left in place for > 3 weeks or
repositioned through endoscopic or percutaneous proce-
dures. Grade C refers to those POPFs that require reop-
eration or lead to single or multiple organ failure and/or
mortality attributable to the pancreatic fistula.
Pancreaticojejunostomy generally involves a combin-
ation of suture between the pancreatic parenchyma and
the seromuscular layer of the jejunum, and duct-to-mu-
cosa suture. A clinical study regarding the various kinds
of pancreaticojejunostomy was reported for the purpose
of lowering the frequency of POPF; nevertheless, the
frequency of more than grade B POPF remains
approximately 10–20% [13–15]. In soft pancreas patients
with unexpanded pancreatic ducts, the risk is further el-
evated to over 30% [16].
Polyglycolic acid (PGA) felt is a felt-like absorbable su-
ture-reinforcing material. It is generally used to reinforce
sutures of fragile tissues such as the lung, bronchi, liver
and gastrointestinal tract and to reinforce a wide range
of tissue defects. Regarding pancreaticojejunostomy
using a PGA felt, the incidence of POPF formation was
lower in some retrospective studies [17, 18]; on the other
hand, no significant difference was found other studies
[19, 20]. As already described, pancreaticojejunostomy
with reinforcement of a PGA felt aimed at reducing
POPF has yet to be fully examined.
We reported significant decreases of POPF thanks to
the ingenuity of pancreaticojejunostomy in a single-insti-
tution matched historical-control study [21]. In distal
pancreatectomy, we have verified the effect of oral food
intake on POPF [22], and are participating in a multi-
centre prospective randomized trial associated with
POPF [23].
Here, we have devised a new method using double-
coated PGA felt for pancreaticojejunostomy in patients
with a small diameter of the main pancreatic duct. This
study is a multicentre randomized phase III trial in Japan
and Republic of Korea to verify the usefulness of this
double coating of PGA felt preventing POPF.
Methods/design
Aim
The aim of the PLANET-PJ trial is to evaluate the effi-
cacy of PGA felt reinforcement in preventing POPF after
pancreaticojejunostomy in patients with a main pancre-
atic duct less than 3 mm in diameter and a soft pancreas
undergoing partial pancreatoduodenectomy.
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Study population
Patients undergoing pancreaticojejunostomy without a
dilated main pancreatic duct (MPD) (so-called soft
pancreas) and parenchymal atrophy or pancreatitis are
eligible. There are no restrictions to the type of
disease. Detailed eligibility criteria are presented in
Table 1.
Study design
This study is designed as a multicentre randomized
phase III trial in Japan and Republic of Korea. A total of
514 patients will be included, and 31 leading institutions
and hospitals in Japan and Republic of Korea will partici-
pate in the PLANET-PJ trial (Additional file 1). The
registration period is scheduled for 3 years, and the fol-
low-up period will be 3 months.
Randomization
After confirmation of eligibility, including written in-
formed consent, patients are randomized in a 1:1 alloca-
tion ratio to either group A (polyglycolic acid felt
reinforcement) or group B (control), preoperatively.
Central randomization and registration will be applied,
using the Electronic Data Capture (EDC) system (Seoul
National University, Medical Research Collaborating
Center). After being assessed for eligibility at registra-
tion, patients will be centrally randomized to either
group A or group B. To minimize background bias be-
tween the two groups, this study is stratified for institu-
tion and suturing method to approximate the pancreas
and the jejunum (mattress or non-mattress). We use
Pocock and Simon’s minimization method for random
assignment and the Mersenne Twister for random num-
ber generation. See Fig. 1 for a flow diagram of the
PLANET-PJ trial.
All patients are blinded to the surgical approach
that they will be receiving, and they are required to
sign an informed consent before enrolling in this
study [24]. Blinding of the surgeons is not possible,
owing to the different techniques used during the op-
eration. However, the result assessment will be made
by an independent researcher (TS) who will be
blinded to the surgical procedures. Physicians, study
nurses and statisticians are blinded to the surgical ap-
proach as well.
Endpoints
This clinical trial will primarily evaluate the incidence of
POPF. The secondary endpoints will be the length of drain
placement after surgery, length of the hospital stay after
surgery, incidence of overall biochemical leak and POPF,
incidence of POPF by each suturing method to approxi-
mate the pancreas and the jejunum, incidence of delayed
gastric emptying (DGE), incidence of intraabdominal
abscess, incidence of post-pancreatectomy haemorrhage
(PPH), incidence of interventional drainage, incidence of
overall postoperative complications, incidence of POPF-
Table 1 Eligibility criteria
Inclusion criteria
(1) Pancreatic or periampullary lesions requiring
pancreatoduodenectomy
(2) Planned pancreaticojejunostomy including duct-to-mucosa
anastomosis
(3) Main pancreatic duct diameter≤ 3 mm on the left side of the
portal vein on preoperative imaging (computed tomography or
magnetic resonance imaging)
(4) Performance status (Eastern Cooperative Oncology Group scale):
0–1 at the time of enrolment
(5) Age 20 years or older
(6) Adequate organ function
(a) Leukocyte count ≥ 2500 mm3, ≤ 14000mm3
(b) Haemoglobin ≥ 9.0 g/dl
(c) Platelet count ≥ 100,000mm3
(d) Total bilirubin ≤ 2.0 mg/dl (does not apply to patients with
obstructive jaundice)
(e) Creatinine ≤ 2.0 mg/dl




(2) Laparoscopic or laparoscope-assisted pancreatoduodenectomy
(3) Pancreatic parenchymal atrophy or calcification due to chronic
pancreatitis
(4) Neoadjuvant treatment including chemotherapy or radiotherapy
(5) History of upper abdominal surgery (both of open and
laparoscopic) except cholecystectomy
(6) Emergency surgery
(7) Arterial reconstruction such as superior mesenteric artery,
common hepatic artery or celiac artery
(8) Severe ischaemic heart disease
(9) Severe liver dysfunction due to liver cirrhosis or active hepatitis
(10) Severe respiratory disorder requiring oxygen
(11) Chronic renal failure with dialysis
(12) Requiring resection of other organs (liver or colon) during
pancreatoduodenectomy
(13) Immunosuppressive treatment
(14) History of severe hypersensitivity to polyglycolic acid felt or
fibrin glue
(15) Other severe drug allergies
(16) Contrast media allergy for both iodine and gadolinium
(17) Active duplicate cancer thought to affect adverse events
(18) Severe psychological or neurological disease
(19) Drug or alcohol abuse
(20) Planned use of octreotide
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related complications (POPF + DGE+ abscess + PPH), inci-
dence of 3-month mortality and incidence of reoperation.
Biochemical leak, POPF [12], DGE [25] and PPH [26]
are defined and graded according to the International
Study Group of Pancreatic Surgery (ISGPS) criteria and
Clavien–Dindo classification [27]. Postoperative compli-
cations other than POPF, DGE and PPH are graded ac-
cording to Clavien–Dindo classification [27]. Then, the
comprehensive complication index was evaluated as a
secondary outcome [28].
Subgroup analyses will be planned per anastomosis or
pancreatic stent. These secondary outcomes will be
exploratory.
Sample size estimation
This trial was designed to evaluate the efficacy of group A
compared with group B in terms of the incidence of POPF.
In cases using PGA felt at the pancreaticojejunostomy in
partial pancreatoduodenectomy with an MPD diameter of
3mm or less, the incidence of POPF was 15.5% [18, 19].
The incidence of POPF was 26% in a previous report with-
out PGA felt at the pancreaticojejunostomy in partial pan-
creatoduodenectomy with an MPD diameter of 3mm or
less [29]. When statistical analysis is performed for a
significance level of α = 0.05 (two-sided) in a superiority de-
sign, 231 patients are calculated to be required per arm,
with a power 100(1 – β) of more than 80%, under the as-
sumption that a small number of patients may be deemed
ineligible and may thus be excluded from the analysis.
Furthermore, as approximately 10% of the patients are ex-
pected to be ineligible for surgery, the sample size was
eventually increased to 514 patients (257 patients per arm).
This sample size was calculated using software PASS 15.0.6.
In the evaluation of the secondary endpoints, a hy-
pothesis test will be used for comparison between both
groups, although formal power calculations for these
analyses have not been performed.
Statistical analysis plan
All statistical analyses will be performed using the full
analysis set (FAS) under the intention-to-treat principle.
The significance level of this test is 5% (two-sided) and
the confidence coefficient is 0.95. The Wilcoxon rank-
sum test will be used for comparison of continuous vari-
ables. The Fisher’s exact test will be used for comparison
of categorical variables. Kaplan–Meier curves will be
used to represent time-to-event variables, and hazard ra-
tios and 95% confidence intervals will be estimated by
Fig. 1 Flow diagram of the PLANET-PJ trial. ECOG Eastern Cooperative Oncology Group, PGA polyglycolic acid
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In both groups, the subjects are patients without dilated
MPD (so-called soft pancreas) and parenchymal atrophy
or pancreatitis. There are no regulations regarding the
type of disease, the degree of lymph node dissection,
portal vein resection or the type of suture used. Patients
undergoing pancreaticojejunostomy with duct-to-mu-
cosa anastomosis will be eligible for inclusion; however,
there are no regulations regarding the suturing method
to approximate the pancreas and the jejunum (Kakita
method, two-layer suturing method, modified Blumgart
method, etc.). Pancreaticogastrostomy and the invagin-
ation method are not permitted.
The MPD diameter will be measured before pancreati-
cojejunostomy to reconfirm that it is 3 mm or less. If it
exceeds 3 mm, the protocol treatment will be termi-
nated. There are no restrictions to the placement of pan-
creatic stent (yes/no) and the method (external/internal).
The presence or absence of a pancreatic stent is regis-
tered postoperatively as intraoperative information in
the EDC system. Even if the policy of the suturing
method to approximate the pancreas and the jejunum is
changed during surgery (mattress or non-mattress), the
study treatment shall be continued. The anastomotic
drains will be placed in all enrolled patients. There are
no restrictions to the type and number of anastomotic
drains; however, a closed-type drain must be used and
must be placed around the pancreaticojejunostomy.
In group B, pancreaticojejunostomy will be performed
as already described. In group A, during pancreaticojeju-
nostomy: a 0.3-mm thick PGA felt (Neoveil®; GUNZE,
Japan) will be pasted on the ventral side and the dorsal
side of pancreatic parenchyma, through which suture be-
tween the pancreatic parenchyma and the jejunum will
be performed (Fig. 2a); and before abdominal closure
(after completion of all reconstruction, after washing in
the abdominal cavity), a 0.15-mm-thick PGA felt will be
further covered around the anastomotic site and fibrin
glue will be sprayed (Fig. 2b).
Intraoperative photography
To confirm that the surgical procedure is performed cor-
rectly by central judgement, intraoperative photographs of
the surgical fields will be needed in both groups. The anasto-
motic site of pancreaticojejunostomy will be photographed
with a digital camera immediately after pancreaticojejunost-
omy (both in groups A and B) and after spraying with fibrin
glue (only in group A). Photographs will be sent by email to
the administrative office (University of Toyama) within 4
weeks after surgery. Central judgement will be conducted
every 6 months for all of the registered patients by the mem-
bers of the central review committee. If the procedure is not
Fig. 2 Method using double-coated polyglycolic acid (PGA) felt during pancreaticojejunostomy. a A 0.3-mm thick PGA felt (Neoveil®; GUNZE,
Japan) will be pasted on the ventral side and the dorsal side of the pancreatic parenchyma. b Before abdominal closure, a 0.15-mm thick PGA felt
will be further covered around the anastomotic site and fibrin glue will be sprayed
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appropriate, the case will be excluded. The central judge-
ment committee has respective members in charge of group
A or group B. They will judge to exclude the inappropriate
cases from a per-protocol analysis set, and we will review the
number of excluded cases in the final report/publication.
Postoperative management
Blood/ biochemical examination and amylase level mea-
surements of anastomotic drains will be performed on
postoperative day (POD) 1 and POD 3. If the amylase
level of anastomotic drains on POD 1 is 5000 IU/L or
less, we recommend drain removal on POD 4–6. In pa-
tients with POPF or infectious signs that require thera-
peutic drainage, drainage should be continued. Prior to
drain removal, a CT/MRI check must be performed to
confirm the intra-abdominal situation. After POD 4,
blood/biochemical examination or drain amylase-level
measurements just before removing the anastomotic
drains are performed according to the physician’s discre-
tion. Use of a prophylactic antimicrobial agent after sur-
gery or prophylactic routine exchange of anastomotic
drains shall not affect the definition of POPF to be clas-
sified. In the case of continued drainage after POD 4–6,
we recommend drain removal when either or both of
the following conditions continue for 2 consecutive days:
the amylase level in the drainage fluid is less than three
times the upper limit of institutional normal serum
amylase level; or the amount of the drainage fluid is 20
mL/day or less.
Postoperative follow-up
Follow-up 3months after surgery to observe the occur-
rence of postoperative complications, re-hospitalization
or re-operation will be a part of the protocol treatment.
Three months after surgery, contrast-enhanced CT (or
MRI) will be taken to measure the MPD diameter in
both groups. See Fig. 3 for the study calendar.
Interim analysis
Interim analysis will be performed once, taking multipli-
city into account using the Lan–DeMets method with
O’Brien and Fleming type boundaries. The monitoring
committee will independently review the interim analysis
report and stop the trial early if necessary.
Monitoring
Central monitoring will be performed once a year by an
independent data monitoring committee. The monitor-
ing committee will collect information on the status of
accumulation, inclusion/exclusion criteria, serious ad-
verse events, etc., and strive to provide feedback to par-
ticipating institutions for early resolution if there are any
problems. The monitoring committee will also report
the serious adverse events to the committee of efficacy
and safety assessment. The PLANET-PJ trial will be con-
ducted in Japan and Republic of Korea; therefore, moni-
toring committees will be established in each country.
Fig. 3 Study calendar. CT/MRI computed tomography/magnetic resonance imaging, POD postoperative day
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Efficacy and safety assessment
If a serious adverse event occurs after the start of the
study, or a problem that requires early termination of
the entire study occurs, the committee of efficacy and
safety assessment will deliberate with the principal inves-
tigator. The committee of efficacy and safety assessment
will also be set up in both countries and will discuss the
results of monitoring and adverse events during the trial.
Discussion
Partial pancreatoduodenectomy is an advanced proced-
ure requiring a high level of surgical technique. With the
development of surgical techniques and perioperative
management in recent years, surgical-related mortality
rates have become less than 5%. Nevertheless, the inci-
dence of complications remains high at 30–65% [1–10].
In particular, the high frequency of POPF is problematic,
because the various complications according to POPF,
including intraabdominal haemorrhage or intraabdom-
inal abscess, can be fatal.
There is no evidence to prove a safe and reliable pro-
cedure of pancreaticojejunostomy. We planned this
study to evaluate the efficacy of a new method using
double-coated PGA reinforcement to prevent POPF after
pancreaticojejunostomy. This trial is a multicentre ran-
domized phase III trial in Japan and Republic of Korea
that is the first international study in pancreatic surgery.
This study is designed to evaluate the usefulness of
group A (double coating of PGA felt) compared with
group B (without PGA felt) in terms of the frequency of
POPF as the primary endpoint. Upon randomization, the
eligible subjects will be stratified by the institution and
suturing method to approximate the pancreas and the
jejunum (mattress or non-mattress). The reason is that
these factors may affect the incidence of POPF. There-
fore, we will set these two factors for allocation in this
study for appropriate analysis and evaluation. Moreover,
we randomize the patients preoperatively after evaluat-
ing appropriateness in the CT image just before surgery.
It would be ideal to randomize during surgery after the
measurement of the diameter of the main pancreatic
duct, but this is very difficult because of the situation of
the participating facilities in this study.
All patients are blinded to the surgical approach
that they will be receiving, and they are required to
sign an informed consent before enrolling in this
study [24]. However, blinding of the surgeons is not
possible, owing to the different techniques used dur-
ing the operation. This can be a potential source of
inevitable bias. The anastomotic drains will be placed
in all enrolled patients because measurement of the
amylase level in the anastomotic drains is required
for assessment of POPF, although recent meta-analysis
revealed that pancreatic resection with or without
abdominal drainage results in similar rates of mortal-
ity, morbidity and reintervention [30].
Industry-funded RCTs are prone to report positive re-
sults. This study is funded by GUNZE LIMITED. Probst
et al. [31] reported that industry involvement in surgical
research has to ensure scientific integrity and independ-
ence, and has to be based on full transparency. In this
study, employees of GUNZE LIMITED did not have ac-
cess to the data during the trial, did not participate in
the data analysis and did not participate in the prepar-
ation of the manuscript other than to review it. The de-
sign and implementation of this study is being
conducted only by the investigators (TF, KS, J-YJ, MK,
MS, SS, SY, HY, HK, SCK, JSH, Y-SY, JSP, HKH).
GUNZE LIMITED has nothing to do with this study
other than funding.
If the usefulness of this new double coating of PGA
felt method is proven, we believe that this trial may
provide evidence for lowering the incidence of POPF,
to the great benefit of patients who undergo partial
pancreatoduodenectomy and of the medical economy.
Furthermore, in patients with malignant disease, post-
operative adjuvant chemotherapy might be introduced
promptly, to lead to prolongation of overall survival
(Additional file 2).
Trial status
The PLANET-PJ trial was opened in October 2018. At
the time of submission of this article (November 2018),
the protocol is version 1.1. The completion date is esti-
mated to be June 2021.
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Additional file 1: Institution list (DOCX 15 kb)
Additional file 2: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents (DOC 123 kb)
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